Aristotle University Of Thessaloniki (AUTH)
Ορθολογική επαναστόχευση φαρμάκων βασισμένη σε μεθόδους πρωτεϊνωματικής ανάλυσης βιολογίας και φαρμακολογίας συστημάτων σε λεμφοειδείς νεοπλασίες
Abstract
dc:descriptionThe present thesis focuses on the study of lymphoid neoplasms and the investigation of drug repurposing, aiming to improve the existing therapeutic approaches for these diseases. Even today, lymphoid neoplasms remain a significant cause of death with increasingly high incidence rates. In recent years, the development of holistic analysis technologies (-omics) has made it possible to better understand the complex biological processes leading to neoplasms. Specifically, proteomic analysis promises to provide a deeper understanding of the action of key bioactive molecules within the cell, the proteins. The research methodology included both computational (in silico) and experimental (in vitro) analyses. The computational analysis gathered data on Chronic Lymphocytic Leukemia (CLL) with the goal of identifying prognostic proteins and discovering new therapeutic targets. This data is used to find new therapeutic molecules with an emphasis on already approved therapies (drug repurposing methodology). The experimental analysis evaluated the actions of the repurposed drugs in various cell lines using molecular and biochemical techniques, as well as mass spectrometry analysis. For the computational analysis, a detailed recording of recent proteomic studies in CLL was initially performed. The goal was to capture the current knowledge regarding protein expression related to the development and progression of the disease. Based on this analysis, three studies were selected and utilized, which compared the proteomic signatures of patients with CLL to those of healthy individuals. Through the integration of the data, differentially expressed proteins were identified that could serve as potential biomarkers for the diagnosis or prognosis of the disease, such as YEATS2, PIGR, BTF3, SNRPA, and NUTF2. Furthermore, the computational analysis suggests the repurposing of the drugs Bosutinib, Vorinostat, and Panobinostat for the treatment of CLL. In the experimental analysis, the data derived from the computational approach is utilized, with emphasis given on the molecular, pharmacological and biochemical analysis of the identified molecular drugs. Initially, the compound Fostamatinib (R406) was evaluated in six different cell lines from three lymphoid neoplasms. R406 demonstrated statistic significant cytotoxic activity, and thus it was further studied in synergy with Nutlin-3a (N3a), a well-documented anti- cancer agent. Similarly, cannabidiol (CBD) was also shown effective in killing cancer cells, achieving significant cytotoxic effects across all studied cell lines and especially Mec1 cell line (CLL). Additionally, proteomic analysis of the cells exposed to CBD was conducted using mass spectrometry, revealing that CBD affects multiple cellular processes. Specifically, it appears to influence mRNA alternative splicing, a crucial process for protein production, apoptosis (cell death), and mitochondrial function, which is vital for energy production in cells. In conclusion, this doctoral dissertation provides a combined analysis of multiple -omics data at both in silico and in vitro levels in lymphoid neoplasms. The findings highlight the potential for a better understanding of cancer cells and support the possible discovery of new anticancer therapies through drug repurposing.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mavridou, Dimitra
- Μαυρίδου, Δήμητρα
Subjects
dc:subject × 22- Επαναστόχευση φαρμάκων
- Πρωτεϊνωματική
- Φαρμακολογία
- Λεμφοειδείς νεοπλασίες
- Φαρμακευτική
- Drug repurposing
- Proteomics
- Pharmacology
- Lymphoid neoplasms
- Pharmaceuticals
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Μοριακή ιατρική
- Επιστήμες Υγείας
- Επιστήμες υγείας, γενικά
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
- Molecular Medicine
- Health Sciences
- Health sciences, general
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57634